强化化疗对比标准化疗后奥拉帕利靶向HRD在III期乳腺癌的III期试验
SUBITO是一项开放标签随机对照III期试验,纳入174例III期HER2阴性HRD乳腺癌患者,随机接受强化烷化剂化疗联合自体干细胞救援(IACT)或标准化疗后奥拉帕利维持。
要点
- IACT组3-4级血小板减少(99% vs 19%)和中性粒细胞减少(95% vs 61%)显著更高。
- 标准治疗联合奥拉帕利在III期HER2阴性HRD乳腺癌中疗效与IACT相当且毒性更低。
核心结论
- 在III期HER2阴性HRD乳腺癌中,强化化疗联合自体干细胞救援未优于标准化疗后奥拉帕利维持治疗。
研究设计与样本
- 开放标签、随机对照III期试验,纳入荷兰8家医院和1家癌症中心及法国1家癌症中心,共174例患者随机1:1接受IACT(n=87)或标准化疗后奥拉帕利(n=87)。
- 纳入18-66岁新诊断IIIA-C期HER2阴性HRD乳腺癌无远处转移患者,要求胚系BRCA1/2致病突变或肿瘤HRD检测证据。
主要发现
- IACT组3-4级不良事件:血小板减少80例(99%)vs 18例(19%),中性粒细胞减少77例(95%)vs 56例(61%),贫血50例(62%)vs 37例(41%)。
- 治疗相关严重不良事件:IACT组38/81例(47%)vs 奥拉帕利组24/91例(26%),发热性中性粒细胞减少最常见(IACT组36例44% vs 奥拉帕利组11例12%)。
- 无治疗相关死亡报告。
临床怎么用
- 对于III期HER2阴性HRD乳腺癌,标准化疗后奥拉帕利维持可作为优选方案,无需采用强化化疗联合自体干细胞救援。
局限性
- 研究未收集患者种族数据,可能影响结果外推。
- 试验仍在进行但已停止入组,随访时间中位41个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this approach remains superior to a contemporary HRD-targeting regimen in patients with HER2-negative breast cancer with HRD. METHODS: This open-label, randomised, controlled, phase 3 trial included patients from eight hospitals and one cancer centre in the Netherlands and one cancer centre in France. Newly diagnosed patients aged between 18-66 years with stage IIIA-C, HER2-negative, HRD breast cancer without distant metastases who had a pathogenic germline BRCA1/2 mutation or evidence of a HRD tumour on testing were randomly assigned (1:1) to receive IACT or conventional chemotherapy using interactive response technology. IACT comprised dose-dense alkylating chemotherapy (ddAC; four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks intravenously), supported by 6 mg prophylactic pegfilgrastim subcutaneously every 2 weeks. 2 weeks after stem cell mobilisation, patients received two IACT cycles 3 weeks apart (3000 mg/m2 cyclophosphamide on day 1, 250 mg/m2 thiotepa on day 2, and 400 mg/m2 carboplatin intravenously on days 1 and 2), followed by autologous stem cell transplantation. Conventional chemotherapy comprised four ddAC cycles, followed by four cycles of intravenous carboplatin area under the curve 6 every 3 weeks, and 80 mg/m2 paclitaxel every week for 12 weeks (carboplatin-paclitaxel intravenously), followed by 1 year of oral olaparib (300 mg twice daily). All patients proceeded to surgery and radiotherapy according to local practice. Stratification factors were treatment centre, age, stage, and oestrogen receptor status. The primary endpoint was overall survival in the intention-to-treat population (all randomly allocated patients). The trial was registered at ClinicalTrials.gov, NCT02810743, and is ongoing, but is closed for inclusion. FINDINGS: From Jan 25, 2017, through to Oct 5, 2023, 356 patients were screened for eligibility, and 174 patients were randomly assigned to receive IACT (n=87) or olaparib (n=87). All patients were female, and median age was 42 years (IQR 37-50). We did not ask explicit informed consent for collecting data on ethnicity of patients, because we focused on a very rare patient subgroup and therefore used pragmatic eligibility criteria following standard General Data Protection Regulation. 28 (32%) in the IACT group and 22 (25%) patients in the olaparib group had germline BRCA1/2 mutations. With a median follow-up of 41 months (IQR 27-59), the 4-year overall survival was 77·0% (95% CI 67·7-87·7 in the IACT group and 76·4% (66·9-87·4) in the olaparib group (hazard ratio for death 1·11 [95% CI 0·57-2·17]; p=0·37).The most common grade 3-4 adverse events were platelet count decreased (80 [99%] in the IACT group vs 18 [19%] in the olaparib group), neutrophil count decreased (77 [95%] in the IACT group vs 56 [61%] in the olaparib group), and anaemia (50 [62%] in the IACT group vs 37 [41%] in the olaparib group). Treatment-emergent serious adverse events occurred in 38 (47%) of 81 patients in the IACT group versus 24 (26%) of 91 patients in the olaparib group. Febrile neutropenia was the most common serious adverse event in both groups (36 [44%] in the IACT group; 11 [12%] in the olaparib group). No treatment-related deaths were reported. INTERPRETATION: These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib. FUNDING: Dutch Cancer Society, the Dutch Ministry of Health, the Netherlands Organization for Health Research and Development, A Sister's Hope, [Z]aan de Wandel, AstraZeneca, MSD, and Eurocept Pharmaceuticals.
引用
- Seefat RL, Vliek SB, de Jong VMT, et al. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42372741. doi:10.1016/S1470-2045(26)00131-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。